Numab Therapeutics AG

Biotechnology ResearchSwitzerland51-200 Employees

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. 

Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.

Sign up for free to view info

Email Format Employee directory